A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

被引：0
|
作者：
Ross, Robert W. [1 ]
Srinivasan, Ramaprasad [2 ]
Vaishampayan, Ulka [3 ]
Bukowski, Ronald [4 ]
Rosenberg, Jonathan [5 ]
Eisenberg, Peter [6 ]
Logan, Theodore [7 ]
Srinivas, Sandhya [8 ]
Stein, Mark [9 ]
Mueller, Thomas [10 ]
Keer, Harold N. [10 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Natl Canc Inst, Urol Oncol Branch, Bethesda, MD USA
[3] Karmanos Canc Ctr, Detroit, MI USA
[4] Cleveland Clin, Cleveland, OH USA
[5] Univ Calif San Francisco, San Francisco, CA USA
[6] California Canc Ctr, Greenbrae, CA USA
[7] Indiana Univ, Ctr Canc, Indianapolis, IN USA
[8] Stanford Univ, Ctr Canc, Stanford, CA 94305 USA
[9] Inst Canc Res, New Brunswick, NJ USA
[10] Exelixis Inc, San Francisco, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3511S / 3511S
页数：1
相关论文
共 50 条
  • [31] First-in-human study of TU2218, TGFbRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
    Oh, D. Y.
    Lee, E.
    Tolcher, A. W.
    Kim, K. P.
    Kim, H. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S633 - S633
  • [32] A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies.
    Salgia, Ravi
    Hong, David
    Sherman, Steven I.
    Ng, Chann
    Frye, John
    Janish, Linda
    Ratain, Mark
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3385S - 3385S
  • [33] SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    Lee, Jae-Lyun
    Cancel, Mathilde
    Verheijen, Remy B.
    Mellemgaard, Anders
    Ottesen, Lone
    Frigault, Melanie M.
    L'Hernault, Anne
    Szijgyarto, Zsolt
    Signoretti, Sabina
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma
    Wang, Gangyang
    Sun, Mengxiong
    Jiang, Yafei
    Zhang, Tao
    Sun, Wei
    Wang, Hongsheng
    Yin, Fei
    Wang, Zhuoying
    Sang, Weilin
    Xu, Jing
    Mao, Min
    Zuo, Dongqing
    Zhou, Zifei
    Wang, Chongren
    Fu, Zeze
    Wang, Zongyi
    Duan, Zhenfeng
    Hua, Yingqi
    Cai, Zhengdong
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (04) : 979 - 993
  • [35] Phase 2 study of XL184 (BMS-907351) in a cohort of patients (pts) with hepatocellular carcinoma (HCC)
    Van Cutsem, E.
    Su, W. C.
    Davis, J.
    Haas, N.
    Samuel, T. A.
    Tsao, C. J.
    Yang, T. S.
    Brandy, H.
    Mann, G.
    Cohn, A.
    EJC SUPPLEMENTS, 2010, 8 (07): : 129 - 130
  • [36] Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET (vol 20, pg 2959, 2014)
    Xiang, Q.
    Chen, W.
    Ren, M.
    Wang, J.
    Zhang, H.
    Deng, D. Y.
    CLINICAL CANCER RESEARCH, 2016, 22 (09) : 2312 - 2312
  • [37] Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2
    Navis, Anna C.
    Bourgonje, Annika
    Wesseling, Pieter
    Wright, Alan
    Hendriks, Wiljan
    Verrijp, Kiek
    van der Laak, Jeroen A. W. M.
    Heerschap, Arend
    Leenders, William P. J.
    PLOS ONE, 2013, 8 (03):
  • [38] A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
    Kang, Hyunseok
    Ahn, Myung-Ju
    Muzaffar, Jameel
    Keam, Bhumsuk
    Bowles, Daniel W.
    Wong, Deborah J. L.
    Ho, Alan Loh
    Kim, Sung-Bae
    Worden, Francis P.
    Yun, Tak
    Sari, Suha
    Conlan, Maureen G.
    Hanna, Glenn J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
    Shah, Manish A.
    Wainberg, Zev A.
    Catenacci, Daniel V. T.
    Hochster, Howard S.
    Ford, James
    Kunz, Pamela
    Lee, Fa-Chyi
    Kallender, Howard
    Cecchi, Fabiola
    Rabe, Daniel C.
    Keer, Harold
    Martin, Anne-Marie
    Liu, Yuan
    Gagnon, Robert
    Bonate, Peter
    Liu, Li
    Gilmer, Tona
    Bottaro, Donald P.
    PLOS ONE, 2013, 8 (03):
  • [40] Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study
    Jhawer, M.
    Kindler, H. L.
    Wainberg, Z.
    Ford, J.
    Kunz, P.
    Tang, L.
    McCallum, S.
    Kallender, H.
    Shah, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345